Indian Journal of Critical Care Case Report

Register      Login

VOLUME 3 , ISSUE 3 ( May-June, 2024 ) > List of Articles


Euglycemic Diabetic Ketoacidosis—A Rare Cause for Delayed Extubation: Case Report

Marutheesh Mallappa, Gayathri K Reddy, Murali Jayaraman, Harish M Maheshwarappa

Keywords : Case report, Diabetic ketoacidosis, Euglycemic, Sodium/glucose cotransporter-2 inhibitors

Citation Information : Mallappa M, Reddy GK, Jayaraman M, Maheshwarappa HM. Euglycemic Diabetic Ketoacidosis—A Rare Cause for Delayed Extubation: Case Report. 2024; 3 (3):83-85.

DOI: 10.5005/jp-journals-11006-0105

License: CC BY-NC 4.0

Published Online: 03-05-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Aim and background: Euglycemic diabetic ketoacidosis (DKA) is ketoacidosis in individuals with near-normal blood sugar levels, making it difficult to diagnose. This can result in overlooked cases. Case description: A 46-year-old male with diabetes and hypertension presented with abdominal pain and fever. Gallstones and bile duct dilation were found. Elevated glucose levels and sugar in urine were detected. Gangrenous changes in the gallbladder were discovered during surgery. Severe metabolic acidosis required a ventilator and intensive care unit (ICU) transfer. Euglycemic DKA was considered due to sodium/glucose cotransporter-2 inhibitor (SGLT-2i) use. Treatment included fluids, insulin, and dextrose infusion. Extubation was successful the next day. Conclusion: Euglycemic DKA should be considered in critically ill patients with diabetes, even with low blood sugar or no ketones in the urine. Diagnosis involves assessing metabolic acidosis, measuring serum ketones, and ruling out other causes. Clinical significance: Euglycemic DKA is a metabolic emergency that poses a serious risk to life. Anesthesiologists, emergency medicine and intensive care units struggle with the absence of hyperglycemia because it might delay diagnosis and treatment, which harms patient outcomes, and its incidence has risen with the use of SGLT-2i.

PDF Share
  1. Modi A, Agrawal A, Morgan F. Euglycemic Diabetic Ketoacidosis: A Review. Curr Diabetes Rev 2017;13(3):315–321. DOI: 10.2174/1573399812666160421121307
  2. Barski L, Eshkoli T, Brandstaetter E, et al. Euglycemic diabetic ketoacidosis. Eur J Intern Med 2019;63:9–14. DOI: 10.1016/j.ejim.2019.03.014
  3. Plewa MC, Bryant M, King-Thiele R. Euglycemic Diabetic Ketoacidosis 2021.
  4. Nasa P, Chaudhary S, Shrivastava PK, et al. Euglycemic diabetic ketoacidosis: a missed diagnosis. World J Diabetes 2021;12(5):514–523. DOI: 10.4239/wjd.v12.i5.514
  5. Thiruvenkatarajan V, Meyer EJ, Nanjappa N, et al. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review. Br J Anaesth 2019;123(1):27–36. DOI: 10.1016/j.bja.2019.03.028
  6. Milder DA, Milder TY, Kam PCA. Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations. Anaesthesia 2018;73(8):1008–1018. DOI: 10.1111/anae.14251
  7. Handelsman Y, Henry RR, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract 2016;22(6):753–762. DOI: 10.4158/EP161292.PS
  8. Kerridge R, Whyte I, Prior F, et al. The good, the bad, and the ugly: sodium-glucose cotransporter-2 inhibitors (gliflozins) and perioperative diabetes. Anaesth Intensive Care 2018;46(2):155–158. DOI: 10.1177/0310057X1804600202
  9. Tan H, Acharya S. Perioperative cessation of sodium-glucose cotransporter-2 inhibitors: 72 hours or seven days? Anaesth Intensive Care 2018;46(4):425. PMID: 29966119.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.